(19)
(11) EP 1 809 672 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
11.08.2010 Bulletin 2010/32

(45) Mention of the grant of the patent:
09.09.2009 Bulletin 2009/37

(21) Application number: 05800673.5

(22) Date of filing: 04.11.2005
(51) International Patent Classification (IPC): 
C07K 16/38(2006.01)
(86) International application number:
PCT/EP2005/011808
(87) International publication number:
WO 2006/048300 (11.05.2006 Gazette 2006/19)

(54)

ATAZANAVIR CONJUGATES AND ANTIBIBODIES USEFUL IN IMMUNOSSAY

ATAZANAVIRKONJUGATE UND ANTIKÖRPER, DIE SICH FÜR EINEN IMMUNASSAY EIGNEN

CONJUGUES D'ATAZANAVIR ET ANTICORPS UTILES DANS UN DOSAGE IMMUNOLOGIQUE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 05.11.2004 US 982611

(43) Date of publication of application:
25.07.2007 Bulletin 2007/30

(73) Proprietors:
  • Roche Diagniostics GmbH
    68305 Mannheim (DE)
    Designated Contracting States:
    DE 
  • F. Hoffmann-La Roche AG
    4070 Basel (CH)
    Designated Contracting States:
    AT BE BG CH CY CZ DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR 

(72) Inventors:
  • ROOT, Richard, T.
    Fishers, IN 46038 (US)
  • HUI, Raymond
    Indianapolis, IN 46220 (US)


(56) References cited: : 
EP-A- 1 207 394
US-A1- 2004 127 689
 WO-A-03/006506
   
  • AKEB FATIMA ET AL: "Quantification of plasma and intracellular levels of the HIV protease inhibitor ritonavir by competitive ELISA." JOURNAL OF IMMUNOLOGICAL METHODS. 1 MAY 2002, vol. 263, no. 1-2, 1 May 2002 (2002-05-01), pages 1-9, XP004354380 ISSN: 0022-1759
  • POIRIER J-M ET AL: "SIMULTANEOUS DETERMINATION OF THE FIVE HIV-PROTEASE INHIBITORS: AMPRENAVIR, INDINAVIR, NELFINAVIR, RITONAVIR,AND SAQUINAVIR IN HUMAN PLASMA BY SOLID-PHASE EXTRACTION AND COLUMN LIQUID CHROMATOGRAPHY" THERAPEUTIC DRUG MONITORING, NEW YORK, NY, US, vol. 22, no. 4, August 2000 (2000-08), pages 465-473, XP001069299 ISSN: 0163-4356
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).